Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 9/20 | 0.43 |
| ▸ | CDK1 | P06493 | 8/20 | 0.43 |
| ▸ | AURKA | O14965 | 6/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343517 | 1.00 | MERTK (0.43) | MERTKCDK1AURKACCNB1CDK2 | |
| SCHEMBL31299830 | 0.91 | CDK1 (0.50) | CDK1AURKACCNB1CDK2KDR | |
| SCHEMBL10167422 | 0.90 | MERTK (0.41) | MERTKCDK1AURKACCNB1CDK2 | |
| SCHEMBL343382 | 0.87 | MERTK (0.57) | MERTKCDK1AURKACCNB1CDK2 | |
| SCHEMBL31299866 | 0.87 | MERTK (0.57) | MERTKCDK1AURKACCNB1CDK2 | |
| SCHEMBL343383 | 0.87 | MERTK (0.57) | MERTKCDK1AURKACCNB1CDK2 | |
| Hydrochloric Acid SCHEMBL31299841 | 0.86 | MERTK (0.56) | MERTKCDK1AURKACCNB1CDK2 | |
| SCHEMBL341734 | 0.84 | STK3 (0.47) | MERTKCDK1AURKACCNB1SYK | |
| SCHEMBL342481 | 0.84 | CDK2 (0.47) | MERTKCDK1AURKACCNB1CDK2 | |
| SCHEMBL342482 | 0.84 | CDK2 (0.47) | MERTKCDK1AURKACCNB1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | claimed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | MERTK 1098/4885CDK1 10/4885AURKA 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.